Navigation Links
DiagnoCure announces fourth quarter and full year 2008 earnings conference call and webcast
Date:12/5/2008

QUEBEC CITY, Dec. 5 /PRNewswire-FirstCall/ - DiagnoCure Inc. (TSX: CUR), a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services, announced today that the Company will release its fourth quarter and fiscal 2008 year end results on December 17, 2008, at approximately 5:00 p.m. (ET). This release will be followed by a conference call, which will be held on December 18, 2008, at 10:30 a.m. (ET). The conference will begin with a brief presentation, followed by a question-and-answer period.

The event will be webcast live through DiagnoCure's website at www.diagnocure.com, through a link on the Investors page - Presentations and Conferences.

For those who wish to take part in the conference call for the Q&A period, please dial (514) 807-8791 (Montreal area), (416) 644-3416 (Toronto area) or the toll-free number (800) 732-9307.

For those unable to participate, a replay of the audio conference will also be available on DiagnoCure's website as of December 19, 2008, also through a link on the Investors page - Presentations and Conferences.

About DiagnoCure

DiagnoCure (TSX: CUR) is a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services that increase clinician and patient confidence in making critical treatment decisions. DiagnoCure Oncology Laboratories, a subsidiary of DiagnoCure Inc., recently launched the Previstage(TM) GCC Colorectal Cancer Staging Test, the first GCC-based molecular test for the management of colorectal cancer. The Company also has a strategic alliance with Gen-Probe (NASDAQ: GPRO) for the development and commercialization of a second-generation prostate cancer test using PCA3, DiagnoCure's proprietary molecular marker. Thi
'/>"/>

SOURCE DIAGNOCURE INC.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. DiagnoCure to webcast presentation at the Piper Jaffray Health Care Conference on December 3, 2008
2. DiagnoCure to present at the JMP Securities Healthcare Focus Conference on October 6, 2008
3. Diagnocure announces sponsorship of inaugural undy 5,000 run - Partnership with the Colon Cancer Alliance creates patient awareness of previstage(TM) GCC staging test
4. DiagnoCures GCC marker for the staging of colorectal cancer discussed at the Eastern Cooperative Oncology Group
5. DiagnoCure announces second quarter 2008 results
6. DiagnoCure to host Q2 2008 earnings conference call and webcast
7. DiagnoCures molecular diagnostic tests - PCA3 and GCC - discussed at scientific meetings
8. Susan G. Komen for the Cure(R) Announces Recipients of 2008 Komen Brinker Award for Scientific Distinction
9. Universal Health Realty Income Trust Announces Marc D. Miller Appointed to Board of Trustees and Dividend Increase
10. OneMedPlace announces panels for "OneMedForum 2009: Disrupters and Drivers in Eight Areas of Medical Technology" -- CEOs and investors to meet in unique format of focused sessions
11. Integrated Healthcare Holdings, Inc. Announces New Chief Executive Officer

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/7/2009)...n the current economic climate, many Americans are... spending money on what that they consider to be a...David D. Kim believes that it’s very importa...ve treatment to improve their health, and he is tr...ients in this tough economy by offering reasonable...
(Date:11/6/2009)..., VANCOUVER, Nov. 6 /PRNewswire-FirstCall/ - Cardi... announced that it will report financial results f...he morning of Monday, November 9, 2009. Cardiome w...am Eastern (6:00am Pacific) on that day to discuss...ease dial 416-695-7806 or 888-789-9572 and referen...
(Date:11/6/2009)...lth bill loaded with pledge-breaking tax hikes ,...oday by Americans for Tax Reform: ,, By formally...ident Barack Obama effectively announced that the ..., During the campaign, Obama made a "firm pledge" ...aking less than $250,000 per year: ,, "I can mak...
(Date:11/6/2009)... Healthcare Trust of America, Inc. (the "REIT"), a...trust, announced the execution of a Purchase and S...al office building located in Englewood, Colorado ...ce Medical Center is located within the Englewood ...opment district. Hampden Place is located near the...
(Date:11/6/2009)...dreds of Thousands of Idahoans Struggling with Hig...Premiums ,, BOISE, Idaho, Nov. 6 As the debat...and the House readies to vote on critical health c...s calling on Idaho,s U.S. Representatives to suppo...re for America Act (H.R. 3962), which will close t...
Breaking Medicine News(10 mins):Health News:Dallas Bariatric Surgeon Offers Multiple Options for Patients Considering Weight Loss Surgery in a Rough Economy 2Health News:Dallas Bariatric Surgeon Offers Multiple Options for Patients Considering Weight Loss Surgery in a Rough Economy 3Health News:Cardiome to Release Third Quarter Results 2Health News:Cardiome to Release Third Quarter Results 3Health News:ATR: Obama Lied, His Tax Pledge Died 2Health News:ATR: Obama Lied, His Tax Pledge Died 3Health News:Healthcare Trust of America, Inc. Executes Agreement to Acquire a 66,339 SF Medical Office Building Located in Englewood, Colorado 2Health News:Healthcare Trust of America, Inc. Executes Agreement to Acquire a 66,339 SF Medical Office Building Located in Englewood, Colorado 3Health News:AARP Calls On Idaho's U.S. Reps To Back House Health Care Reform Bill 2
...ugh it has been a known fact that caffeine in coff... was not clear how exactly this happens.// Scient... Center, Dallas have found out exactly how caffein...down and sleep sets in. Caffeine, present in the t...
...an scientists have found out that having green tea...of cancer of prostate gland in males.// Of t...r of the prostate gland, only one person developed...green tea called EGCG had been suspected to preven...
...of pancreatic cancer is enhanced by eating process...Center// at the University of Hawaii in Honolulu. ...th pancreatic cancer, but this is the first time p...ents that process the meat for long time preservat...
...ent study had suggested that an increasing waistli...s may// be a strong predictor for atherogenesis an... The study had looked into 557 women for 8.5 yrs t...ner lining of the arteries that make them hard cau...
...lways have appreciated the value of taking risks a...nal// Evolution and Human Behavior had pointed out... women do not like to have them as spouses. I... and friends. Tasks were divided into heroic risk ...
...ent study had pointed out the fact that herbal pre...es// may react badly when taken along with medicat... out that herbal preparations and alternate medici...he conventional drug manufacturers leading to poor...
Other Medicine News:
(Date:11/6/2009)...wswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc...Tuesday, November 10, 2009 at 8:30 a.m. EST to dis...business outlook for the remainder of 2009. Ron B...ll host the call. Keryx will announce its financi...e issued prior to the call. ,, In order to part...
(Date:11/6/2009)...swire-FirstCall/ -- Cyberonics, Inc. (Nasdaq: CYB...inancial results for the second quarter ended Octo...010 on Wednesday, November 18, 2009 at 5:00 PM EST...iscuss those results on Thursday, November 19, 200...Quarter Results Conference Call Instructions ,...
(Date:11/6/2009)...ewswire/ -- NexBio Inc., in collaboration with sci...vention (CDC), St. Louis University, and the Unive...n of two articles in the peer-reviewed journal PLo...AS181 (Fludase ® ) may play a potentially imp...e Pandemic Influenza A(H1N1) and drug-resistant in...
Breaking Medicine Technology:Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2009 Financial Results on Tuesday, November 10, 2009 at 8:30 a.m. EST 2Cyberonics Announces Conference Call to Discuss Fiscal Year 2010 Second Quarter Financial Results 2NexBio(R) Publishes Two Articles Showing DAS181 (Fludase(R)*) Potently Inhibits Pandemic Influenza A(H1N1) and NAI-Resistant Influenza Viruses 2NexBio(R) Publishes Two Articles Showing DAS181 (Fludase(R)*) Potently Inhibits Pandemic Influenza A(H1N1) and NAI-Resistant Influenza Viruses 3NexBio(R) Publishes Two Articles Showing DAS181 (Fludase(R)*) Potently Inhibits Pandemic Influenza A(H1N1) and NAI-Resistant Influenza Viruses 4Orexigen 28R 29 Therapeutics Announces In Licensing of Key Patents to Further Strengthen its Intellectual Property Estate for Contrave 28R 29 48582 1Orexigen 28R 29 Therapeutics Announces In Licensing of Key Patents to Further Strengthen its Intellectual Property Estate for Contrave 28R 29 48582 2Orexigen 28R 29 Therapeutics Announces In Licensing of Key Patents to Further Strengthen its Intellectual Property Estate for Contrave 28R 29 48582 3Senate Bill to Protect Patients Healthcare by Amending Medicare Coverage 48578 1Senate Bill to Protect Patients Healthcare by Amending Medicare Coverage 48578 2Senate Bill to Protect Patients Healthcare by Amending Medicare Coverage 48578 3Medivation Completes Enrollment in Confirmatory Pivotal Phase 3 CONNECTION Trial of Dimebon in Patients With Alzheimers Disease 12580 1Medivation Completes Enrollment in Confirmatory Pivotal Phase 3 CONNECTION Trial of Dimebon in Patients With Alzheimers Disease 12580 2Medivation Completes Enrollment in Confirmatory Pivotal Phase 3 CONNECTION Trial of Dimebon in Patients With Alzheimers Disease 12580 3Medivation Completes Enrollment in Confirmatory Pivotal Phase 3 CONNECTION Trial of Dimebon in Patients With Alzheimers Disease 12580 4
...s show improved insulin sensitivity and lower gluc...therapies , , KALAMAZOO, Mich., May 14 Metabolic...day that its lead compound, MSDC-0160, can improve...s in humans without the side effects of current th... to preliminary data derived from the company,s Ph...
...B offers Cimzia(R) (certolizumab pegol), a treatme...ctive rheumatoid arthritis and moderate to severe ...y designed prefilled syringe resulting from the UC...hritis patients directly involved with UCB and OXO...led syringe , , -- Cimzia(R) prefilled syringe ...
Other Medicine Technology:Metabolic Solutions Development Company Announces Preliminary Results from Phase IIa Clinical Trial 2Metabolic Solutions Development Company Announces Preliminary Results from Phase IIa Clinical Trial 3Video: Partnership Unites UCB with Consumer Product Innovator OXO(R) 2Video: Partnership Unites UCB with Consumer Product Innovator OXO(R) 3Video: Partnership Unites UCB with Consumer Product Innovator OXO(R) 4Video: Partnership Unites UCB with Consumer Product Innovator OXO(R) 5Video: Partnership Unites UCB with Consumer Product Innovator OXO(R) 6Video: Partnership Unites UCB with Consumer Product Innovator OXO(R) 7Video: Partnership Unites UCB with Consumer Product Innovator OXO(R) 8Video: Partnership Unites UCB with Consumer Product Innovator OXO(R) 9Video: Partnership Unites UCB with Consumer Product Innovator OXO(R) 10Video: Partnership Unites UCB with Consumer Product Innovator OXO(R) 11
Clinaseal
...l ventilated floor-standing centrifuge. Mobile spa...ge choice of accessories, analog controls, large b...own (JOUAN patented pendulum system), guard barrie...itation, rugged motor, tough steel casing with che...
... microscopes utilize the infinity-corrected optica...n cell checking. Olympus has taken this one step f...approach with the capability of a fluorescence ill...ital imaging and video monitoring. The CKX41 is ro...
The Clipper
Medicine Products: